Kamali Chance, Head of Global Biosimilars Regulatory Strategy at Quintiles, discusses the latest updates in biosimilars regulation followed by Biosimilar development, a CRO perspective John Patava, Head of Biosimilar Intelligence and Capabilities at Quintiles describing the current status of biosimilar medicine development and what implications this may have for clinical practice in the future.

Please click here to download a copy of the slides: Download